- Home
- GRNT vs CTMX Comparison
GRNT vs CTMX Comparison
Compare GRNT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNT
- CTMX
- Stock Information
- Founded
- GRNT 2013
- CTMX 2008
- Country
- GRNT United States
- CTMX United States
- Employees
- GRNT N/A
- CTMX N/A
- Industry
- GRNT Blank Checks
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- GRNT Finance
- CTMX Health Care
- Exchange
- GRNT Nasdaq
- CTMX Nasdaq
- Market Cap
- GRNT 675.9M
- CTMX 596.2M
- IPO Year
- GRNT N/A
- CTMX 2015
- Fundamental
- Price
- GRNT $5.19
- CTMX $3.64
- Analyst Decision
- GRNT Buy
- CTMX Strong Buy
- Analyst Count
- GRNT 1
- CTMX 6
- Target Price
- GRNT $8.00
- CTMX $6.50
- AVG Volume (30 Days)
- GRNT 452.9K
- CTMX 3.9M
- Earning Date
- GRNT 11-06-2025
- CTMX 11-06-2025
- Dividend Yield
- GRNT 8.49%
- CTMX N/A
- EPS Growth
- GRNT N/A
- CTMX 50.22
- EPS
- GRNT 0.29
- CTMX 0.24
- Revenue
- GRNT $427,828,000.00
- CTMX $113,631,000.00
- Revenue This Year
- GRNT $35.82
- CTMX N/A
- Revenue Next Year
- GRNT $10.41
- CTMX N/A
- P/E Ratio
- GRNT $18.03
- CTMX $15.28
- Revenue Growth
- GRNT 19.33
- CTMX N/A
- 52 Week Low
- GRNT $4.52
- CTMX $0.40
- 52 Week High
- GRNT $7.00
- CTMX $4.62
- Technical
- Relative Strength Index (RSI)
- GRNT 46.61
- CTMX 50.34
- Support Level
- GRNT $5.07
- CTMX $3.35
- Resistance Level
- GRNT $5.29
- CTMX $4.45
- Average True Range (ATR)
- GRNT 0.16
- CTMX 0.37
- MACD
- GRNT -0.00
- CTMX -0.06
- Stochastic Oscillator
- GRNT 53.28
- CTMX 30.00
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.